GoodRx Holdings Inc (NASDAQ: GDRX) closed the day trading at $8.35 up 7.19% from the previous closing price of $7.79. In other words, the price has increased by $+0.56 from its previous closing price. On the day, 3875481 shares were traded. GDRX stock price reached its highest trading level at $8.52 during the session, while it also had its lowest trading level at $8.02.
Ratios:
For a better understanding of GDRX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.90 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 23.98. For the most recent quarter (mrq), Quick Ratio is recorded 7.12 and its Current Ratio is at 7.12. In the meantime, Its Debt-to-Equity ratio is 0.93 whereas as Long-Term Debt/Eq ratio is at 0.91.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on March 01, 2024, Upgraded its rating to Overweight and sets its target price to $10 from $7 previously.
On February 26, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $8.
BofA Securities Downgraded its Buy to Underperform on January 02, 2024, whereas the target price for the stock was revised from $8 to $4.50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 30 when Wagner Scott bought 21,652 shares for $5.76 per share. The transaction valued at 124,806 led to the insider holds 182,900 shares of the business.
Wagner Scott bought 26,348 shares of GDRX for $155,482 on Nov 29. The insider now owns 161,248 shares after completing the transaction at $5.90 per share. On Nov 28, another insider, Wagner Scott, who serves as the insider of the company, bought 4,157 shares for $6.00 each. As a result, the insider paid 24,940 and bolstered with 134,900 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GDRX now has a Market Capitalization of 3.39B and an Enterprise Value of 3.43B. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.39 while its Price-to-Book (P/B) ratio in mrq is 4.32. Its current Enterprise Value per Revenue stands at 4.57 whereas that against EBITDA is 31.52.
Stock Price History:
Over the past 52 weeks, GDRX has reached a high of $9.37, while it has fallen to a 52-week low of $4.14. The 50-Day Moving Average of the stock is 6.41, while the 200-Day Moving Average is calculated to be 6.09.
Shares Statistics:
Over the past 3-months, GDRX traded about 1.70M shares per day on average, while over the past 10 days, GDRX traded about 2.48M shares per day. A total of 92.36M shares are outstanding, with a floating share count of 76.22M. Insiders hold about 81.23% of the company’s shares, while institutions hold 13.30% stake in the company. Shares short for GDRX as of Feb 15, 2024 were 9.72M with a Short Ratio of 5.70, compared to 9.6M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.39% and a Short% of Float of 11.84%.
Earnings Estimates
Current recommendations for the stock of the company come from 15 analysts. On average, analysts expect EPS of $0.07 for the current quarter, with a high estimate of $0.1 and a low estimate of $0.04, while EPS last year was $0.07. The consensus estimate for the next quarter is $0.08, with high estimates of $0.11 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.44 and $0.15 for the fiscal current year, implying an average EPS of $0.3. EPS for the following year is $0.38, with 15 analysts recommending between $0.51 and $0.29.
Revenue Estimates
15 analysts predict $193.22M in revenue for the current quarter. It ranges from a high estimate of $197.45M to a low estimate of $188.16M. As of the current estimate, GoodRx Holdings Inc’s year-ago sales were $183.99M, an estimated increase of 5.00% from the year-ago figure. For the next quarter, 15 analysts are estimating revenue of $197.37M, an increase of 4.10% less than the figure of $5.00% in the same quarter last year. There is a high estimate of $204.69M for the next quarter, whereas the lowest estimate is $193M.
A total of 19 analysts have provided revenue estimates for GDRX’s current fiscal year. The highest revenue estimate was $809.23M, while the lowest revenue estimate was $760.1M, resulting in an average revenue estimate of $789.96M. In the same quarter a year ago, actual revenue was $750.26M, up 5.30% from the average estimate. Based on 18 analysts’ estimates, the company’s revenue will be $849.96M in the next fiscal year. The high estimate is $921.5M and the low estimate is $814.4M. The average revenue growth estimate for next year is up 7.60% from the average revenue estimate for this year.
